Standard chemotherapy has been ineffective for improving the poor 10-year survival rate of patients with indolent lymphoma. However, a wider choice of therapeutic modalities has become recently available, including immunotherapy with monoclonal antibodies and allogeneic peripheral blood stem cell transplantation. Accordingly, a sensitive prognostic indicator is required to identify high-risk patients and to help design new therapeutic approaches for them. We previously reported that the serum nm23-H1 protein level was an independent prognostic factor for aggressive lymphoma. The present study was performed to assess the clinical implications of this protein on indolent lymphoma and whether it can be used to classify the aggressiveness of the disease in order to assist in the individualization of therapy. A total of 130 patients with indolent lymphoma were enrolled in this multicenter study. The serum nm23-H1 protein level was significantly higher in patients with indolent lymphoma than in a normal control group. In addition, indolent lymphoma patients with higher nm23-H1 levels had worse overall and progression-free survival rate than those with lower nm23-H1 levels. Therefore, nm23-H1 in serum may be useful for identifying a distinct group of patients at high risk. Leukemia (2001) 15, 832-839.
Introduction
Indolent lymphoma is characterized by slow progression. However, since standard chemotherapy achieves poor progression-free survival and overall survival after 10 years of follow-up, 1 this disease is difficult to cure. The international prognostic index (IPI) 2 reported by Shipp in 1993 has been accepted in many countries as a prognostic model that reasonably predicts the clinical outcome for aggressive lymphoma. The IPI model is based on five dependent prognostic factors (age, performance status, number of extranodal sites, Ann Arbor stage, and serum LDH concentration) and it can identify patients with non-Hodgkin's lymphoma (NHL) in four different risk groups (ie low (L), low-intermediate (L-I), high-intermediate (H-I), and high risk (H)). The model has been extensively applied to identify aggressive lymphoma and indolent lymphoma with a poor prognosis. Recently, new therapies have been used to treat indolent lymphoma patients with risk factors that might indicate a poor prognosis, eg immunotherapy with monoclonal antibodies, autologous stem cell transplantation combined with high-dose chemotherapy, and allogeneic peripheral blood stem cell transplantation for younger patients. [3] [4] [5] A wide choice of modalities has recently become available for the treatment of indolent lymphoma. Therefore, it is now necessary to stratify patients based on their prognosis and to individualize therapy.
We previously found that a differentiation inhibitory factor (I-factor) purified from a differentiation-resistant mouse myeloid leukemia cell line was identical to nm23 protein. 6, 7 In an immunohistochemical study of nm23-H1 in malignant lymphoma, the expression of this protein was significantly increased in Hodgkin's disease and high-grade NHL as compared with that in low-grade NHL. 8 Recently, we established an enzyme-linked immunosorbent assay (ELISA) for determining the serum level of nm23-H1 protein. 9, 10 Using this assay, we have already demonstrated that the serum nm23-H1 level is significantly higher in patients with indolent and aggressive NHL, and acute myelogenous leukemia (AML) than in normal controls. 9, 10 (Table 1 ) This assay may be useful for determining the therapeutic strategy for aggressive NHL, since the prognosis is worse with a high nm23-H1 level. 9 In the present multicenter study, the association between the serum nm23-H1 protein level and other prognostic markers of NHL was assessed. The serum level of nm23-H1 was elevated in patients with indolent lymphoma, and the serum level was significantly correlated with the clinical outcome, suggesting that nm23-H1 may be a valuable prognostic factor for predicting the outcome in indolent lymphoma.
Materials and methods

Patients
We measured nm23-H1 levels in consecutive 130 untreated indolent type lymphoma patients who were managed by the Adult Lymphoma Treatment Study Group (ALTSG) in Japan. Indolent lymphoma was of the B cell lineage in all patients, including 86 with follicular grade I, 42 with follicular grade II, and two with small lymphocytic lymphoma according to the REAL schema. 11 Patients with mantle cell lymphoma were excluded from this analysis since it is an independent disease unit and the types of therapy applied to treat this disease differ from those for other types of indolent lymphoma. All slides were re-examined by two hematopathologists to confirm the diagnosis of indolent lymphoma and for uniform cytologic classification. The median age was 66 years (range: 18-80 years). Clinical staging was performed according to the Ann Arbor classification system. 11 Evaluation included a complete history and physical examination: chest roentgenography; bone marrow aspiration and biopsy; computed tomography of the chest, abdomen and pelvis; hemogram and differential counts; and routine biochemistry tests. The subjects were all patients with stage II to IV, in whom chemotherapy was indicated. The IPI could be determined in NHL cases.
2 Indolent lymphoma was in most cases treated with single agent (cyclophosphamide : 3 patients) or cyclophosphamide, vincristine, and prednisone (COP: 60 patients). In addition to chemotherapy, 67 patients received megavoltage radiotherapy. Patients were followed up at intervals of several months. Re-evaluation included physical examination, hemo- 
Enzyme-linked immunosorbent assay (ELISA) for human nm23-H1
We determined the serum level of nm23-H1 protein by ELISA, as described previously. 9, 10 Measurements were performed at the Department of Immunology, SRL Inc (Tokyo, Japan). Briefly, 96-well plates (Corning, Corning, NY, USA) were coated with a monoclonal anti-nm23-H1 antibody (Seikagakukougyo, Tokyo, Japan), washed four times with phosphate-buffered saline (PBS), and incubated with 25% Block Ace (Dainihon Seiyaku, Osaka, Japan). Serum samples were diluted two-fold with PBS, and then 50 l aliquots were added to the wells. After incubation at room temperature for 1 h, the wells were washed four times with PBS containing 0.05% Tween 20 (T-PBS). Samples were then incubated at room temperature for 1 h with a polyclonal anti-nm23-H1 antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), washed four times with T-PBS, and incubated with alkaline phosphatase-conjugated anti-rabbit IgG (BioRad, Richmond, CA, USA). After washing four times with T-PBS, alkaline phosphatase activity was detected using diethanolamine as a substrate and an alkaline phosphatase-detecting kit (BioRad). The reaction was stopped by addition of 50 l of 0.4 N NaOH. Absorbance was measured at 405-415 nm with a correction wavelength of 620-630 nm using a Microplate reader.
Soluble interleukin-2 receptor (IL-2R) was measured with a sandwich ELISA 12 and soluble CD44 was measured by sandwich ELISA using a sCD44std ELISA kit (Bender MedSystems, Vienna, Austria).
Statistical analysis
The patients' characteristics were compared using the chisquare test. Overall survival (OS) was defined as the interval from initiation of therapy to the time of death or last followup. Progression was defined as a 25% increase in the product of the two largest tumor diameters. Progression-free survival (PFS) was calculated from the date of entry to the date of the first physical or radiographic evidence of disease progression, death or the last follow-up visit. Survival analysis was performed using the Kaplan-Meier method. 13 The statistical significance of differences in survival was determined by the logLeukemia rank and generalized Wilcoxon's tests.
14 Differences between groups were evaluated by the Mann-Whitney U-test (nonparametric analysis), 15 or Fisher's exact test, and P Ͻ 0.05 was taken to indicate significance. A multivariate analysis of the prognosis was performed using Cox's proportional-hazards regression model. 16 All calculations were performed with SAS software (version 6.10, SAS Institute, Cary, NC, USA).
Results
Correlations between the nm23-H1 level and other serum markers in indolent lymphoma
The serum level of nm23-H1 was significantly elevated in the patients with indolent lymphoma (n = 130, mean ± s.d.; 19.31 ± 22.34 ng/ml) compared with that in the healthy controls. (n = 45, 3.89 ± 4.06 ng/ml; P = 0.00001). Furthermore, this level was higher in follicular grade I (n = 86, 20.92 ± 24.12 ng/ml; P = 0.00001), follicular grade II (n = 42, 18.47 ± 32.41 ng/ml; P = 0.046), and small lymphocytic (n = 2, 11.36 ± 8.56 ng/ml; P = 0.025) than in the healthy controls, without any significant difference among the three histological types. When the correlation between nm23-H1 and other known serum markers of NHL, as well as correlations among the known serum markers were assessed, there was a weak correlation between serum nm23-H1 protein and sIL-2R (r = 0.2424, P = 0.0055), but not between the nm23-H1 level and LDH, beta2-microglobulin (MG), or sCD44. There was a correlation between sIL-2R and LDH (r = 0.3628, P = 0.0002), and between sIL-2R and beta2-MG (r = 0.4647, P = 0.0001), while beta2-MG was also correlated with sCD44 (r = 0.3452, P = 0.0069) ( Table 2) . Table 3 shows the clinicopathological features of the 130 patients. The cut-off value of LDH was the upper limit of the normal range at each institution. An increased LDH level was correlated with the nm23-H1 protein level (P = 0.0016). In addition, the nm23-H1 protein level increased as the disease stage increased (P = 0.043). With respect to the IPI classification, the nm23-H1 level was higher in the H-I + H risk group than in the L + L-I risk group (P = 0.007), although there was no significant difference between lymphomas with different histology (P = 0.1971). The nm23-H1 protein level was independent on the response to therapy (CR vs non-CR). These results suggest that the nm23-H1 protein level is associated with the tumor mass and the IPI, but not with the response to therapy.
Relationship between serum nm23-H1 protein and clinicopathological features of indolent lymphoma
We also analyzed the serum nm23-H1 level in relation to histological subgroups (Figure 1a) . The results showed that when the LDH level (normal/elevated) (Figure 1b ) was high and the risk assessed by IPI (Figure 1c) was greater, the serum nm23-H1 level also tended to be higher.
Correlation of nm23-H1 and other prognostic features with survival
For the entire 130 patients, the 9-year overall survival rate was 36.5% and the 7-year progression free survival (PFS) rate was 15.7%. The patients were divided into two groups with different serum nm23-H1 levels using various cut-off values over 12.01 ng/ml, which was the upper limit in the controls (3.89 + 2 s.d.). The cut-off values tested were as follows: 12.01 ng/ml (р12.01, n = 66 vs Ͼ12.01, n = 64), 20.2 ng/ml (2/3 point; р32.5, n = 87 vs Ͼ32.5, n = 43), and 25.0 ng/ml (3/4 point; р25.0, n = 98 vs Ͼ25.0, n = 32). Only two groups based on a cut-off at the 3/4 value differed significantly from each other with respect to overall survival (Wilcoxon test, P = 0.0358, log-rank test, P = 0.0486) and PFS (Wilcoxon test, P = 0.0144, log-rank test, P = 0.0245) ( Figure 2 , Table 4 ). This indicated that the prognosis of indolent lymphoma was poor when the nm23-H1 protein level was 25.0 ng/ml or higher. Since the nm23-H1 level for indolent lymphoma was lower than that for AML and aggressive lymphoma, the cut-off point would have been relatively high. Hence, the cut-off point was set at 25 ng/ml. In the group with a low nm23-H1 level (less than 25 ng/ml) (n = 98), there were 48 patients who underwent COP therapy, 48 patients who underwent COP/radiation therapy, and 2 patients who underwent cyclophosphamide therapy, and in the group with a high nm23-H1 level (higher than 25 ng/ml) (n = 32), there were 12 patients who underwent COP therapy, 19 patients who underwent COP/radiation therapy, and 1 patient who underwent cyclophosphamide therapy. Hence, there were no differences with respect to therapy methods. We also calculated the overall survival and PFS for patients with normal or increased LDH levels. The 5-year overall survival rates for patients with normal and increased LDH levels, were 70.5% and 62.9%, respectively (Wilcoxon and log-rank tests showed no significant differences), and the 5-year PFS was 40.9% and 13.9%, respectively, (Wilcoxon and log-rank tests showed no signifi-
Figure 1
Serum levels of nm23-H1 protein in patients with indolent lymphoma classified according to the histology, LDH level, or international prognostic index.
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Figure 2
Overall survival (a) and progression-free survival (b) curves of patients with indolent lymphoma. High nm23-H1 (Ͼ25 ng/ml) patients (n = 32) had a worse prognosis than low nm23-H1 (р25 ng/ml) patients (n = 98).
cant differences) (Figure 3) . Furthermore, the 5-year overall survival rate was 72.8% for the L + L-I risk group and 54.0% for the H-I + H risk group (Wilcoxon test, P = 0.0234, log-rank test, P = 0.0068), and the 5-year PFS was 30.6% for the L + L-I risk group and 13.4% for the H-I + H risk group (Wilcoxon test, P = 0.0024, log-rank test, P = 0.0071) (Figure 4) .
Univariate analysis was performed to assess the predictive power of nm23-H1 and other prognostic factors. Overall survival was significantly worse for patients who had a WHO PS of 2-4, more than one extranodal site, B symptoms, bulky disease, an IPI classification of H-I + H risk, an sIL-2R of 858.0 U/ml or higher, or an nm23-H1 level of 25.0 ng/ml or higher. The PFS rate was significantly lower in patients with a PS of 2-4, Ann Arbor stage III/IV, more than one extranodal site, an IPI classification of H-I + H risk, an sIL-2R of 858.0 U/ml or higher, or nm23-H1 level of 25.0 ng/ml or higher (Table 4 ). In contrast, classification of the patients based on serum LDH or beta2-MG levels failed to produce any significant difference in either overall survival or PFS. An additional multivariate analysis revealed that the five prognostic factors used to calculate the IPI score and the serum nm23-H1 level were associated with OS (Table 5) . These results indicate that the nm23-H1 level is an independent prognostic factor which may predict both the OS. This was also true for ascertaining the OS in patients with indolent lymphoma.
Discussion
Patients with indolent lymphoma rarely achieve a cure with conventional therapy and many of them eventually die of the disease. 17 It has been reported that the best therapy for indolent lymphoma is to watch and wait unless it becomes symptomatic: the 5-and 10-year actuarial survival rates of untreated patients are 82% and 73%, respectively, under this 'watch and wait' policy. In patients who are initially monitored without treatment; chemotherapy is started after a median of 3 years. 18 Patients who receive intensive chemotherapy may achieve CR, but their survival fails to reach a plateau, indicating that more curative therapy is needed. A mouse-human chimera monoclonal to CD20, IDEC-C2B8 (rituximab), was recently introduced to treat indolent B-lymphoma. When used alone, it has a 50-70% efficacy rate 19 and when used in combination with CHOP therapy, it achieves a high efficacy of 90-100%. 3 However, the improvement of survival still remains unknown due to the need for long-term observation. Therefore, in young patients with chemotherapy-resistant recurrence, the application of allogeneic stem cell transplantation is being investigated. To select candidates for such intensive therapy, a reliable prognostic classification of indolent lymphoma would be useful. As in aggressive NHL, the IPI is used to identify indolent lymphoma patients with a poor prognosis. 20 Many prognostic studies of indolent lymphoma have been performed, and the following parameters were found to be associated with a poor prognosis: older age, poor performance status,
Figure 3
Overall survival (a) and progression-free survival (b) curves of patients with indolent lymphoma based on the serum LDH level.
Figure 4
Overall survival (a) and progression-free survival (b) curves of patients with indolent lymphoma based on the international prognostic index. The biological prognostic factors for aggressive lymphoma have been extensively studied in recent years, but only a few studies have been performed on the prognostic indicators for indolent lymphoma. In patients with indolent lymphoma, prognostic factors have been previously used to choose from among three therapeutic options: the 'watch and wait' method, single-agent chemotherapy, and the COP regimen. However, a wider choice of therapies is becoming available and it is hoped that a curative therapy will eventually be established. Therefore, it seems to be necessary to establish prognostic factors that enable us to identify patients who should be treated differently. The serum nm23-H1 protein level was previously reported as a prognostic factor for aggressive NHL, so the present study was designed to determine whether this protein was also an indicator for indolent lymphoma. We found that the outcome of indolent lymphoma was poor when the nm23-H1 level was high.
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The nm23 gene seems to be involved in the suppression of tumor metastasis, since its expression is decreased in cancer with a propensity for metastasis. 25 The product of this gene is identical to nucleoside diphosphate kinase (NDPK). 26 Decreased expression of nm23-H1 has been associated with an aggressive clinical course in several human tumor cohorts, such as primary breast, primary hepatocellular, ovarian and gastric carcinomas, as well as melanoma. However, the relationship between nm23 expression and tumor metastatic potential is somewhat controversial. In other tumors, such as childhood neuroblastoma and pancreatic carcinoma, increased expression of nm23 is positively correlated with tumor aggressiveness. 27 We previously investigated the relative levels of nm23-H1 and nm23-H2 transcripts in bone marrow and peripheral blood samples from patients with AML, determined the correlation between the expression of nm23 gene and clinical data, and evaluated the importance of nm23 expression as a prognostic factor in AML. 28, 29 We also used ELISA to measure serum nm23-H1 protein levels in 102 AML patients, and found that nm23-H1 protein levels were higher in AML patients than in controls and that patients with high nm23-H1 levels had a poor prognosis. 10 The serum nm23-H1 protein level in malignant lymphoma patients was significantly higher than that in normal controls. In patients with aggressive lymphoma, a high nm23-H1 level was associated with a poor prognosis and seemed to be an independent prognostic indicator of the need for more intensive therapy. The level of this protein can be easily measured using a small quantity of blood prior to therapy. 9 Serum nm23-H1 protein levels in patients with indolent lymphoma in the present study were significantly higher than that of normal controls, but lower than that of patients with either aggressive NHL 9 or AML. 10 In AML patients, the nm23-H1 protein level was closely related to the product of the number of tumor cells and the level of cellular nm23-H1 expression. 10 These results suggest that the more rapid proliferative potential and greater nm23-H1 production in aggressive lymphoma cells account for the higher nm23-H1 protein level than in indolent lymphoma. Also, the tendency was that the more advanced the disease state, the higher the nm23-H1 level, suggesting that this prognostic factor correlates with tumor volume.
There have been only a few studies on the biological prognostic factors for indolent lymphoma. Litam et al 30 reported that a beta2-MG level of 3.0 mg/l or higher was associated with a low complete remission rate and early treatment failure. A high serum IL-6 level is also reported to be associated with a short duration of failure-free survival. 31 In the present study, the overall survival and PFS were significantly lower in the patients with serum nm23-H1 protein levels Ͼ25.0 ng/ml, suggesting that this protein can serve as a new prognostic indicator for indolent lymphoma. Low-risk patients can be treated by immunotherapy with monoclonal antibodies alone or in combination with the CHOP regimen, whereas other therapeutic approaches (including allogeneic bone marrow transplantation) should be considered for the treatment of high-risk patients. The nm23-H1 protein level may be useful for the management of indolent lymphoma in the future, although the value of nm23-H1 protein as a prognostic factor needs to be verified in large-scale prospective studies. It is expected that the prognostic value of nm23-H1 would be increased by using it in combination with other prognostic factors. We are planning to assess such combinations to predict the outcome more accurately than with nm23-H1 protein alone.
